Inclisiran
On 15 October 2020 , the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) adopted a positive opinion , recommending the granting of a marketing authorization for the medicinal product Leqvio , intended for the treatment for primary hypercholesterolaemia or mixed dyslipidaemia . 
<triplet> Committee for Medicinal Products for Human Use <subj> European Medicines Agency <obj> affiliation